September 24, 2024 11:45 ET | Source: Transgene S.A. Transgene S.A.
2024 Half Year Financial Report
Attachment
Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
Transgene to Deliver an Oral Presentation on its Individualized Neoantigen Therapeutic Vaccine TG4050 at the World Vaccine Congress
